Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger… - Blood, The Journal …, 2007 - ashpublications.org
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
[HTML][HTML] Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger, LLR Rix… - Blood, 2007 - Elsevier
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger, LLR Rix… - Blood, 2007 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The BCR-ABL tyrosine kinase inhibitor imatinib
represents the current frontline therapy in chronic myeloid leukemia. Because many patients …
represents the current frontline therapy in chronic myeloid leukemia. Because many patients …
[引用][C] Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U RIX, O HANTSCHEL, T KÖCHER… - Blood, 2007 - pascal-francis.inist.fr
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib
reveal novel kinase and nonkinase targets CNRS Inist Pascal-Francis CNRS Pascal and …
reveal novel kinase and nonkinase targets CNRS Inist Pascal-Francis CNRS Pascal and …
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger, LLR Rix… - …, 2007 - pubmed.ncbi.nlm.nih.gov
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger, R Rix, L Lily… - Blood, 2007 - infoscience.epfl.ch
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
U Rix, O Hantschel, G Dürnberger, RR LL… - Blood, 2007 - europepmc.org
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second …
[引用][C] Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U RIX - Blood, 2007 - cir.nii.ac.jp